<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Making the Case for Moving From IV to Oral Antibiotics

minute read

Meghan Jeffres, PharmD, at the 2023 annual Making a Difference in Infectious Diseases (MAD-ID) conference, cited a litany of data, including studies released within the previous two months, documenting that switching to oral antibiotics after IV treatment for patients requiring prolonged antibiotic courses is advantageous for them and cost-effective for the health system.


Related Stories